Drug
HS 10342
HS 10342: highest development phase Phase 2, developed by Hansoh Pharmaceutical. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Hansoh Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| HS-10342 NCT05044988 | Phase 2 | HR+/HER2- Advanced and/or Metastatic Breast Cancer |
| HS-10342 NCT04060511 | Phase 1 | Advanced Solid Tumor |
Latest
No recent events.
Follow HS 10342 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.